Zhixiang Jintai (688443.SH) has obtained approval for the clinical trial application of its investigational product GR1803 injection (subcutaneous injection).

Wisdom Financial News App, Zhixiang Jintai (688443.SH) announced that recently, the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's investigational product, GR1803 Injection (subcutaneous injection), has been approved for clinical trials.